由Cellares自动化Cell Shuttle™平台完成生产的Cabaletta Bio公司Rese-Cel细胞疗法,已完成对首批患者的给药。这一里程碑标志着自动化生产技术正式进入临床治疗阶段,为细胞疗法的大规模标准化生产开辟了新路径。
由Cellares自动化Cell Shuttle™平台完成生产的Cabaletta Bio公司Rese-Cel细胞疗法,已完成对首批患者的给药。这一里程碑标志着自动化生产技术正式进入临床治疗阶段,为细胞疗法的大规模标准化生产开辟了新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.